Products
Oclacitinib is commercially available in the form of film-coated tablets for dogs (Apoquel). It has been approved in many countries since 2014.
Structure and properties
Oclacitinib (C15H23N5O2S, Mr = 337.4 g/mol) is present in the drug as oclacitinib maleate.
Effects
Oclacitinib (ATCvet QD11AH90) has anti-inflammatory, antiallergic, and antipruritic properties. The effects are due to selective inhibition of Janus kinase 1 (JAK1), which inhibits cytokine function.
Indications
- For the treatment of pruritus occurring in allergic dermatitis in dogs.
- For the treatment of clinical manifestations of atopic dermatitis in dogs.
Dosage
According to the professional information. The tablets initially entered twice daily for two weeks and then only once a day regardless of meals. Dosage is dependent on body weight.
Contraindications
Oclacitinib is contraindicated in hypersensitivity, in dogs less than 12 months of age or body weight less than 3 kg, and progressive malignant neoplasia. For complete precautions, see the drug label.
Interactions
Drug-drug interactions are possible with vaccines.
Adverse effects
Possible adverse effects include digestive disturbances such as diarrhea and poor appetite.
